Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction

American Journal of Cardiology

Volumn 92, Issue 1, 2003, Pages 11-15

  See Jr , Vincent Y ^b   DeNofrio, David ^b   Goldberg, Lee ^b   Chang, Gene ^b   Sasseen, Brett ^b   Kolansky, Daniel M ^b   Pickering, Faith ^b   Kao, Andrew ^b   Loh, Evan ^b   Wilensky, Robert L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CYCLOSPORIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; OKT 3; PREDNISONE; STEROID; TACROLIMUS;

ADULT; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE COURSE; DRUG EFFECT; ECHOGRAPHY; ENDOTHELIUM LESION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASODILATATION;

EID: 0038199679     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00456-9     Document Type: Article

References (17)

1. Wilensky R.L., Tanguay J.F., Ito S., Bartorelli A.L., Moses J., Williams D.O., Bailey S.R., Martin J., Bucher T., Gallant P., et al. The Heparin Infusion Prior to Stenting (HIPS) Trial final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia . Am Heart J. 139:2000;1061-1070.
2. Laufer G., Grablowitz V., Laczkovics A., Miholic J., Heinz G., Wollenek G., Schreiner W., Wolfram J., Wolner E. The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression. J Thor Cardiovasc Surg. 104:1992;241-247.
3. Rudas L., Pflugfelder P.W., McKenzie F.N., Menkis A.H., Novick R.J., Kostuk W.J. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol. 66:1990;1135-1138.
4. Renlund D.G., Bristow M.R., Crandall B.G., Burton N.A., Doty D.B., Karwande S.V., Gay W.A. Jr, Jones K.W., Hegewald M.G., Hagan M.E., et al. Hypercholesterolemia after heart transplantation amelioration by corticosteroid-free maintenance immunosuppression . J Heart Transplant. 8:1989;214-220.
5. Ballantyne C.M., el Masri B., Morrisett J.D., Torre-Amione G. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol. 12:1997;153-160.
6. Galle J., Lehmann-Bodem C., Hubner U., Heinloth A., Wanner C. CyA and OxLDL cause endothelial dysfunction in isolated arteries through endothelin-mediated stimulation of O2-formation. Nephro Dialysis Transplant. 15:2000;339-346.
7. Grady K.L., Costanzo-Nordin M.R., Herold L.S., Sriniavasan S., Pifarre R. Obesity and hyperlipidemia after heart transplantation. J Heart Lung Transplant. 10:1991;449-454.
8. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
9. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., Shiomi M., Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 103:2001;993-999.
10. Pasceri V., Cheng J.S., Willerson J.T., Yeh E.T., Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 103:2001;2531-2534.
11. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
12. Anderson T.J., Meredith I.T., Yeung A.C., Balz F., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
13. Davis S.F., Yeung A.C., Meredith I.T., Charbonneau F., Ganz P., Selwyn A.P., Anderson T.J. Early endothelial dysfunction predicts the development of transplant coronary artery disease at one-year post transplant. Circulation. 93:1996;457-462.
14. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., Cogert G.A., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
15. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Steinbeck G., Seidel D., Reichart B. Simvastastin reduces graft vessel disease and mortality after heart transplantation a four-year randomized trial . Circulation. 96:1997;1398-1402.
16. Teeboken O.E., Struber M., Harringer W., Pichlmaier M.A., Hamerich A. Primary immunosuppresion with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipents. Transplant Proc. 34:2002;1265-1268.
17. Dell C.P. Antiproliferative naphyhopyrans biological activity, mechanistic studies and therapeutic potential . Curr Med Chem. 5:1998;179-194.